References
- Niida H, Nakanishi M. DNA damage checkpoints in mammals. Mutagenesis 2006; 21: 3–9
- Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewski M, de Snoo A, Oldenburg R, et al. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 2002; 31: 55–59
- Vahteristo P, Bartkova J, Eerola H, Syrjakoski K, Ojala S, Kilpivaara O, et al. A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet 2002; 71: 432–438
- Cybulski C, Gorski B, Huzarski T, Masojc B, Mierzejewski M, Debniak T, et al. CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet 2004; 75: 1131–1135
- Baysal B E, DeLoia J A, Willett-Brozick J E, Goodman M T, Brady M F, Modugno F, et al. Analysis of CHEK2 gene for ovarian cancer susceptibility. Gynecol Oncol 2004; 95: 62–69
- de Jong M M, Nolte I M, Te Meerman G J, van der Graaf W T, Mulder M J, van der Steege G, et al. Colorectal cancer and the CHEK21100delC mutation. Genes Chromosomes Cancer 2005; 43: 377–382
- Rudd M F, Sellick G S, Webb E L, Catovsky D, Houlston R S. Variants in the ATM-BRCA2-CHEK2 axis predispose to chronic lymphocytic leukemia. Blood 2006; 108: 638–644
- Bell D W, Varley J M, Szydlo T E, Kang D H, Wahrer D C, Shannon K E, et al. Heterozygous germ line hCHK2 mutations in Li – Fraumeni syndrome. Science 1999; 286: 2528–2531
- Tort F, Hernandez S, Bea S, Martinez A, Esteller M, Herman J G, et al. CHK2-decreased protein expression and infrequent genetic alterations mainly occur in aggressive types of non-Hodgkin lymphomas. Blood 2002; 100: 4602–4608